High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy

Cancer

Volumn 89, Issue 3, 2000, Pages 680-689

  Molina, Arturo ^a   Krishnan, Amrita Y ^a   Nademanee, Auayporn ^a   Zabner, Rachel ^a   Sniecinski, Irena ^a   Zaia, John ^a   Forman, Stephen J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Autologous stem cell transplantation; Highly active antiretroviral therapy; Human immunodeficiency virus; Lymphoma; Myeloablative therapy

Indexed keywords

ANTIRETROVIRUS AGENT; CARMUSTINE; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MYELOABLATIVE AGENT;

ADULT; APHERESIS; ARTICLE; BURKITT LYMPHOMA; CASE REPORT; DRUG MEGADOSE; FEMALE; GRAFT SURVIVAL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; REMISSION; STEM CELL TRANSPLANTATION;

ADULT; ANTI-HIV AGENTS; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4 LYMPHOCYTE COUNT; COMBINED MODALITY THERAPY; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MALE; TRANSPLANTATION, AUTOLOGOUS; VIRAL LOAD;

EID: 0034255163     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000801)89:3<680::AID-CNCR25>3.0.CO;2-W     Document Type: Article

References (55)

1. AIDS-associated non-Hodgkin's lymphoma
2. Epidemiology, clinical characteristics, and management of AIDS-related lymphoma
3. AIDS-related malignant lymphoma: Results of prospective treatment trials
4. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection
5. Non-Hodgkin's lymphoma in a patient population with or at risk for acquired immunodeficiency syndrome: Indications for intensive chemotherapy
6. Human immunodeficiency virus-related lymphoma treatment with intensive chemotherapy. French-Italian Cooperative Group
7. Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type I-related non-Hodgkin's lymphoma: A highly active regimen
8. Chemotherapeutic agents for human immuno-deficiency virus infection: Mechanism of action, pharmaco-kinetics, metabolism, and adverse reactions
9. Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time
10. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastin in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma
11. Phase I/II trial of filagrastim (r-metHu G-CSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin's lymphoma
12. HIV-protease inhibitors
13. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
14. Changing patterns of mortality across Europe in patients infected with HIV-1
15. The use of new antiretroviral therapy in combination with chemotherapy
16. Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma. Evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients
17. Treatment of relapsed/refractory AIDS-related lymphomas with high-dose cytarabine (Ara-C)/cisplatin combination regimens
18. Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: Results from a multi-center Phase II trial
19. Preliminary results of PEG-L-asparginase (Oncsapar) in the treatment of relapsed/refractory AIDS-related lymphomas
20. Autologus bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
21. High-dose therapy followed by autologous peripheral blood stem cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma utilizing unprimed and granulocyte colony-stimulating factor 'mobilized' peripheral blood stem cells
22. The ISHAGE guidelines for CD34+ cell determination by flow cytometry
23. Low temperature storage of bone marrow in nitrogen vapor-phase refrigerators: Decreased temperature gradients with an aluminum racking system
24. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors
25. Long-term follow-up and analysis of prognostic factors after high-dose therapy and peripheral blood stem cell autografting (ASCT) in 58 patients with a history of low grade follicular lymphoma (FLGL)
26. Prediction of systemic fungal infection in allogeneic marrow recipients: Impact of amphotericin prophylaxis in high-risk patients
27. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
28. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy
29. Treatment of acquired immunodeficiency syndrome-related lymphoma with a standard chemotherapy regimen
30. Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma
31. Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma
32. Dose-adjusted EPOCH chemotherapy (CT) in previously untreated HIV-associated non-Hodgkin's lymphoma (HIV-NHL)
33. Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival
34. Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin's lymphomas: A single institution study of 96 patients
35. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: Analysis of AIDS Clinical Trials Group protocol 142 - Low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor
36. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project
37. International Prognostic Index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients
38. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin's lymphoma
39. Liver transplantation in a hemophilia patient with acquired immunodeficiency syndrome
40. Allogeneic bone marrow transplantation combined with multiple anti-HIV treatment in a case of AIDS
41. Autologous bone marrow transplantation in relapsed HIV-related non-Hodgkin's lymphoma
42. Autologous stem cell infusion for acute myelogenous leukemia in an HIV-1 carrier
43. Syngeneic stem cell transplantation for HIV-related lymphoma
44. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma
45. Mobilization of peripheral blood progenitor cells using G-CSF in HIV-1 infected persons
46. Mobilization of CD34+ progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults
47. HIV-1 status and function of G-CSF-mobilized peripheral blood hematopoietic stem cells from asymptomatic HIV-1 infected individuals: Implications for anti-HIV gene therapy
48. Survival benefit of high dose therapy over sequential chemotherapy in poor risk aggressive non-Hodgkin's lymphoma. Final analysis of the prospective LNH87-2 protocol. A GELA study
49. HIV infection does not preclude autologous stem cell transplantation (ASCT) for lymphoma
50. Autologous stem cell transplantation using retrovirus-transduced peripheral blood progenitor cells in HIV-infected persons: Comparison of gene marking post-engraftment with and without marrow ablation
51. Treatment of AIDS lymphoma with high-dose chemotherapy and genetically modified stem cells: A model for evaluation of gene therapy